| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 抗体药物(元) | - | 98,188,258.49 | - | 30,069,639.54 |
| 销售药品(元) | - | - | 45,375,828.79 | - |
| 授权许可(元) | - | 132,509,950.00 | - | - |
| 销售商品(元) | 153,089,005.65 | - | - | - |
| 营业成本(元) | ||||
| 抗体药物(元) | - | 15,790,627.53 | - | 5,301,105.00 |
| 销售药品(元) | - | - | 7,595,005.73 | - |
| 授权许可(元) | - | 290,936.58 | - | - |
| 销售商品(元) | 15,148,449.82 | - | - | - |
| 毛利(元) | ||||
| 抗体药物(元) | - | 82,397,630.96 | - | 24,768,534.54 |
| 销售药品(元) | - | - | 37,780,823.06 | - |
| 授权许可(元) | - | 132,219,013.42 | - | - |
| 销售商品(元) | 137,940,555.83 | - | - | - |
| 毛利率(%) | ||||
| 抗体药物(%) | - | 83.92 | - | 82.37 |
| 销售药品(%) | - | - | 83.26 | - |
| 授权许可(%) | - | 99.78 | - | - |
| 销售商品(%) | 90.10 | - | - | - |
| 收入构成(%) | ||||
| 抗体药物(%) | - | 42.56 | - | 100.00 |
| 销售药品(%) | - | - | 100.00 | - |
| 授权许可(%) | - | 57.44 | - | - |
| 销售商品(%) | 100.00 | - | - | - |
| 毛利构成(%) | ||||
| 抗体药物(%) | - | 38.39 | - | 100.00 |
| 销售药品(%) | - | - | 100.00 | - |
| 授权许可(%) | - | 61.61 | - | - |
| 销售商品(%) | 100.00 | - | - | - |